His strategy was to chemically conjugate the hydrophilic peptide moiety iRGD (a tumor-penetrating peptide that can bind to neuropilin-1 and stimulate tumor tissue penetration) (Sugahara et al., 2009) to the hydrophobic anticancer cargo CPT. This evidence concerns the gene NRP1 and neoplasm.